The Office of the U.S. Trade Representative is seeking public comments on further changes to remove tariffs on additional medical products from China to help address the coronavirus pandemic, Nextgov reported Monday.
“In prior notices, the U.S. Trade Representative has modified the action in the Section 301 investigation of China’s acts, policies, and practices related to technology transfer, intellectual property, and innovation by removing additional duties from medical-care products needed to address the COVID-19 outbreak,” USTR General Counsel Joseph Barloon wrote in a notice set to be published Wednesday on Federal Register.
The agency lifted duties on approximately 200 medical care products, including personal protective equipment, on March 5 in response to the pandemic and would like to request feedback on other goods that could be added to the tariff exemption list.
“Each comment specifically must identify the particular product of concern and explain precisely how the product relates to the response to the COVID-19 outbreak,” according to the notice.
USTR will accept feedback through June 25 and may extend the comment period as appropriate.
